Evidence map›Paper›PMID 34855793›Full record

ArticlePloS one2021

The mucosal barrier and anti-viral immune responses can eliminate portions of the viral population during transmission and early viral growth.

Ryan V Moriarty, Athena E Golfinos, Dane D Gellerup, Hannah Schweigert, Jaffna Mathiaparanam, Alexis J Balgeman, Andrea M Weiler, Thomas C Friedrich, Brandon F Keele, Miles P Davenport and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Ryan V MoriartyDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.ORCID 0000-0001-7100-1906
Athena E GolfinosDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Dane D GellerupWisconsin National Primate Research Center, Madison, Wisconsin, United States of America.
Hannah SchweigertDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Jaffna MathiaparanamDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Alexis J BalgemanDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Andrea M WeilerWisconsin National Primate Research Center, Madison, Wisconsin, United States of America.
Thomas C FriedrichWisconsin National Primate Research Center, Madison, Wisconsin, United States of America.ORCID 0000-0001-9831-6895
Brandon F KeeleAIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD, United States of America.
Miles P DavenportInfection Analytics Program, Kirby Institute for Infection and Immunity, UNSW Sydney, Sydney, NSW, Australia.
Vanessa VenturiInfection Analytics Program, Kirby Institute for Infection and Immunity, UNSW Sydney, Sydney, NSW, Australia.
Shelby L O'ConnorDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.ORCID 0000-0003-0183-5010
University of Wisconsin–Madison · USFrederick National Laboratory for Cancer Research · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
Evaluating immunity elicited by CD8 T Cell responses targeting invariant epitopesR01AI108415 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI SHELBY L OCONNOR · 2014 to 2026
$9.5M
NCI NIH HHS 75N91019D00024NIAID NIH HHS R01 AI108415NIH HHS P51 OD011106
6 · The paper itself

Abstract

Little is known about how specific individual viral lineages replicating systemically during acute Human Immunodeficiency Virus or Simian Immunodeficiency Virus (HIV/SIV) infection persist into chronic infection. In this study, we use molecularly barcoded SIV (SIVmac239M) to track distinct viral lineages for 12 weeks after intravenous (IV) or intrarectal (IR) challenge in macaques. Two Mafa-A1*063+ cynomolgus macaques (Macaca fascicularis, CM) were challenged IV, and two Mamu-A1*001+ rhesus macaques (Macaca mulatta, RM) were challenged IR with 200,000 Infectious Units (IU) of SIVmac239M. We sequenced the molecular barcode of SIVmac239M from all animals over the 12 weeks of the study to characterize the diversity and persistence of virus lineages. During the first three weeks post-infection, we found ~70-560 times more unique viral lineages circulating in the animals challenged IV compared to those challenged IR, which is consistent with the hypothesis that the challenge route is the primary driver restricting the transmission of individual viral lineages. We also characterized the sequences of T cell epitopes targeted during acute SIV infection, and found that the emergence of escape variants in acutely targeted epitopes can occur on multiple virus templates simultaneously, but that elimination of some of these templates is likely a consequence of additional host factors. These data imply that virus lineages present during acute infection can still be eliminated from the systemic virus population even after initial selection.

Indexed as

AnimalsEpitopesFemaleGene Products, tatInjections, IntravenousMacaca fascicularisMacaca mulattaMucous MembraneMutationRNA, ViralSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusT-LymphocytesViral LoadViremiaEpitopesGene Products, tatRNA, Viral

Identifiers

PMID34855793
PMCPMC8639003
OpenAlexW3215876172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.